Published in Oncoimmunology on December 01, 2012
The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol Sci (2014) 0.86
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Cancer immunotherapy comes of age. Nature (2011) 12.35
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell (2011) 2.57
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Proinflammatory effects of IL-10 during human endotoxemia. J Immunol (2000) 1.69
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res (2012) 1.27
Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood (2001) 1.21
Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res (2002) 0.99
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell (2011) 2.57
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther (2010) 1.93
Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol (2007) 1.77
The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol (2002) 1.69
Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res (2003) 1.53
IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol (2009) 1.42
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A (2010) 1.36
IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res (2012) 1.27
MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol (2004) 1.26
Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther (2004) 1.20
mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther (2005) 1.20
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med (2002) 1.11
Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine (2008) 0.95
Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization. J Leukoc Biol (2010) 0.93
Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther (2003) 0.89
Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity. Bioessays (2013) 0.80
Subversion and coercion: the art of redirecting tumor immune surveillance. Curr Top Microbiol Immunol (2011) 0.78
Killing from within. Oncoimmunology (2012) 0.75